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A B S T R A C T
Background
Depression is a common problem in patients with multiple sclerosis (MS). It is unclear which pharmacologic treatment is the most
effective and the least harmful.
Objectives
To investigate the efficacy and tolerability of pharmacologic treatments for depression in patients with MS.
Search methods
We searched the Cochrane Multiple Sclerosis Group’s Trials Register (June 2010), reference lists of relevant articles and conference
proceedings. Regulatory agencies were used as additional sources of information on adverse effects.
Selection criteria
Adequately and quasi-randomized controlled blinded or unblinded trials in children and adults with MS. Experimental intervention:
pharmacologic treatments for depression without restrictions regarding dose, route of administration, frequency, or duration. Control
intervention: placebo treatment or no treatment.
Data collection and analysis
Two teams of reviewers independently assessed trial quality and extracted data. We contacted study authors for additional information.
We collected adverse effects from the trials.
Information about study population, type of intervention, outcome measures, and study design were extracted from the selected studies.
Trial quality was evaluated with the criteria: randomization, allocation concealment, blinding, handling of incomplete outcome data,
freedom from selective reporting and freedom from other bias.
The impact of missing data on the study results was explored with sensitivity analyses comparing the results from the analyses of study
completers with those from best- and worst-case scenarios.
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Main results
Two trials (70 participants) were included. One trial (28 participants) compared treatment with desipramine for five weeks to placebo.
The other trial (42 participants) compared treatment with paroxetine for twelve weeks to placebo. Both trials had a significant number
of patients lost to follow-up or with missing outcome measurements.
There was a trend towards efficacy of both treatments compared to placebo, but this difference was not statistically significant except
for one outcome. Confidence intervals were wide in all analyses and our sensitivity analysis showed that the missing data may have had
an important effect in both trials, with large differences between best-case and worst-case scenarios for all assessed outcomes.
Both treatments were associated with adverse effects, with significantly more patients treated with paroxetine suffering from nausea or
headache. Given the difference in trial duration and type of drug, we decided not to perform a meta-analysis.
Authors’ conclusions
Both desipramine and paroxetine show a trend towards efficacy in depression in MS the short term, but both treatments were associated
with adverse effects, with significantly more patients treated with paroxetine suffering from nausea or headache. Further clinical research
on the treatment of depression in MS is clearly needed. Future trials should address the efficacy and tolerability in the long term and
compare antidepressant treatments head-to-head.
P L A I N L A N G U A G E S U M M A R Y
Drug treatment for depression in multiple sclerosis
Many patients with multiple sclerosis (MS) suffer from depression. In this review we summarized studies of antidepressant drug
treatments in patients with MS. We found two studies that met the inclusion criteria of methodological quality, comprising of a total
of 70 participants: one (28 participants) reported the effects of desipramine, the other (42 participants) the effects of paroxetine. The
two studies showed no improvement of depression with both treatments in the short term (five/twelve weeks). Adverse effects, such
as nausea or headache occurred frequently. Further studies on drug treatment of depression in MS with a longer duration are clearly
needed, as the results may be affected by the small size of participants and by the fact that many participants did not complete the
studies.
B A C K G R O U N D
Depression is a common problem in patients with multiple scle-
rosis (MS) (Siegert 2005). The prevalence of major depression in
patients with multiple sclerosis is higher than in both the general
population and patients with other chronic diseases (Patten 2005).
Several factors may account for the development of depression in
MS. Depression may be the result of the psychological burden
of having a chronic disease with an unpredictable course. On the
other hand, the ongoing structural damage in the central nervous
system (CNS) of patients with MS may also lead to depressive
symptoms (Siegert 2005). Given these considerations, it is uncer-
tain whether depression in patients with MS should be treated as
in the general population, or whether it requires a different ap-
proach.
While pharmacologic treatment can be effective in patients with
MS, it is uncertain which pharmacologic treatment for depression
is the most effective and least harmful in patients with MS. A
systematic review of all relevant randomized controlled trials is the
best way to resolve this uncertainty.
O B J E C T I V E S
To investigate the efficacy and tolerability of pharmacologic treat-
ments for depression in patients with MS.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomized controlled trials on pharmacologic antidepressive
treatment in patients with MS. Double-blind, single-blind or un-
blinded trials were included. Adequately randomized and quasi
randomized trials were included, non-randomized trials were ex-
cluded. Individual patient data were included if available.
Types of participants
Children and adults with a diagnosis of definite MS according to
the Poser (Poser 1983) or McDonald (McDonald 2001) diagnos-
tic criteria, who suffer from depression (either diagnosed by a psy-
chiatrist or defined as a score suggesting depression on a validated
depression scale).
Types of interventions
Experimental intervention: pharmacologic treatments for depres-
sion without restrictions regarding dose, route of administration,
frequency, or duration. Control intervention: placebo treatment
or no treatment. Treatment of all randomized patients (in both
experimental and control groups) with psychotherapy during the
trial was no exclusion criterium, trials with psychotherapy as the
control condition were excluded.
Types of outcome measures
Primary outcomes
Any improvement of depression, as measured with one of the
following depression scales:
• Hamilton Depression Rating Scale (HAM-D) (Hamilton
1960)
• Beck Depression Inventory (BDI) (Beck 1961)
• Zung Self-Rating Depression Scale (Zung SDS) (Zung
1965)
• Symptoms Checklist 90 [Depression Subscale] (SCL-90)
(Derogatis 1973)
• Center for Epidemiological Studies Depression Scale (CES-
D) (Radloff 1977)
• Montgomery-Asberg Depression Rating Scale (MADRS)
(Montgomery 1979)
• The Hospital Anxiety and Depression Scale [Depression
Subscale] (HADS) (Zigmond 1983)
• Inventory of Depressive Symptomatology (IDS) (Rush
1986)
• Major Depression Inventory (MDI) (Bech 2001)
Secondary outcomes
The tolerability of the pharmacologic treatments were investigated
by identifying:
1. The total number of patients experiencing any adverse effect of
the treatment in question
2. The total number of patients experiencing any of following











(l) Death, suicide and suicidality
In order to identify any rare or unexpected adverse effects of the
treatment in question, we collected all adverse effects data reported
in the identified studies during the data extraction phase and dis-
cussed ways to summarise them post hoc.
Search methods for identification of studies
No language restrictions were applied to the search.
Electronic searches
The Trials Search Co-ordinator searched the Cochrane Multiple
Sclerosis Group’s Specialised Register (June 2010).
Keywords are listed in (Appendix 1).
Information on the Cochrane Multiple Sclerosis Group’s Trials
Register, and details of search strategies used to identify trials can
be found in the ’Specialized Register’ section within the Cochrane
Multiple Sclerosis Group’s module.
Searching other resources
(1) Checking reference tables of identified studies.
(2) Handsearching of published abstracts of conference proceed-
ings.
(3) Personal communication with authors of identified studies and
other researchers in the field.
Strategy (3) was used to identify unpublished or ongoing studies.
Regulatory agencies were additional sources of information for
adverse effects:
• In the UK: Current Problems in Pharmacovigilance (
www.mhra.gov.uk);
• In Australia: the Australasian Adverse Drug Reactions
Bulletn (www.tga.gov.au/adr/aadrb.htm);
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• In Europe: the European Public Assessment Reports from
European Medicines Evaluation Agency (www.emea.eu);
• In the US: Food and Drug Administration FDA Medwatch
(www.fda.gov/medwaTCH).
Data collection and analysis
Selection of studies
The titles and abstracts of publications identified by the above
search strategy were assessed independently for inclusion by two
teams of reviewers (MK/JM, and AG/MU/JDK), the full text was
selected for further assessment if the abstract suggested relevance.
Data extraction and management
Information about study population, type of intervention, out-
come measures, and study design were extracted independently
from the selected studies by two teams of reviewers (MK/MU/AG,
and JM/JDK) on a data extraction form. Results were extracted as
raw numbers.
Assessment of risk of bias in included studies
The methodological quality of the studies was evaluated indepen-
dently by two teams of reviewers (MK/JDK/AG and JM/MU)
according to the guidelines described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2008). The cri-
teria used in the assessment of methodological quality were (1)
randomization, (2) allocation concealment, (3) blinding, (4) han-
dling of incomplete outcome data, (5) freedom from selective re-
porting and (6) freedom from other bias.
Measures of treatment effect
For dichotomous outcome measures, treatment effects are ex-
pressed as odds ratios with their 95% confidence interval.
In this review we did not perform meta-analysis, if meta-analysis
is to be performed in future versions of this review, studies will be
summarized using a fixed-effect model. Studies with dichotomous
outcomes will summarized using theMantel-Haenszel fixed-effect
model, and the odds ratiowill be used as summary statistic. Studies
with continuous outcomes will be summarized with the inverse
variance method and the weighted mean difference will be given
as summary statistic.
Dealing with missing data
The impact ofmissing data on the study results was exploredwith a
sensitivity analysis comparing the results from the analyses of study
completers with those from best- and worst-case scenarios. In the
best-case scenario, all missing data from the treatment group were
included as having shown a treatment effect, while those missing
from the placebo group were included as having shown no effect.
In the worst-case scenario missing data from the treatment group
were included as having shown no treatment effect, while those
missing from the placebo group were included as having shown a
treatment effect.
Assessment of heterogeneity
Statistical heterogeneity among the identified studies is tested for
with the chi-squared test. Significant heterogeneity among the
studies is addressed by either refraining from performing a meta-
analysis altogether (in the case of serious heterogeneity), or by
excluding one or a small minority of heterogenous studies. Het-
erogeneity is explored by investigating the influence of subgroups
(men vs. women, adults vs. children, progressive vs. non-progres-
sive MS).
Assessment of reporting biases
Publication bias is assessed with Funnel plots as outlined in the
Cochrane Handbook for Systematic Reviews of Interventions (
Higgins 2008).
R E S U L T S
Description of studies
Results of the search
The search strategy yielded a total of 1217 citations (MEDLINE:
617, EMBASE 539, CINAHL: 5, CENTRAL: 50, Handsearch-
ing: 6). Two teams of reviewers (MK/JDK and AG/JM/MU) pe-
rused titles and abstracts for relevance and independently excluded
1215 citations. All excluded studies did not meet the inclusion
criteria. Two studies were included in this review. Our search of
additional resources yielded no further results. Our search of regu-
latory agency databases yielded no additional information on ad-
verse effects. There were no disagreements regarding study inclu-
sion or exclusion between the two teams or between individual
team members.
Included studies
Ehde and colleagues (Ehde 2008) screened 349 patients with MS
recruited from theWestern MS Center at the University of Wash-
ington, through flyers sent to local neurologists and through re-
gional MS support groups. Patients were eligible to participate in
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the study if they were 18 years or older, had a diagnosis of MS con-
firmed by a neurologist or anMS trained physiatrist and a diagno-
sis of major depressive disorder or dysthymia based on the Struc-
tured Clinical Interview for DSM-IV Axis I Disorders (SCID)
(First 1996). Patients were excluded if they had failed treatment
with paroxetine in the past, were in psychotherapy, were taking
psychotropic medications or more than 50mg or amitriptyline or
equivalent for pain or sleep, had imminent suicidal ideation, were
pregnant, nursing or not using effective contraception, had bipolar
disorder or psychosis based on the SCID, had alcohol or drug-de-
pendence based on the SCID, were participating in another drug
trial, or had used corticosteroids within the two weeks prior to en-
rolment in the study. Forty-two patients met the study criteria and
agreed to participate in the study and were randomized to receive
either paroxetine (22 patients) or placebo (20 patients). The du-
ration of the trial was 12 weeks. Patients were seen at enrolment,
after six weeks and at study end, additional telephone contacts
took place after 1, 2, 4, and 8 weeks. The dosage started at 10mg/
day and was increased if tolerated to up to 40mg/day by the study
psychiatrists. Patients were assessed with the CES-D and HAM-
D scales and several other psychometric scales at enrolment, at six
weeks and at 12 weeks. The HAM-D was used to measure the
primary outcome measures: (1) a reduction of at least 50% of the
HAM-D score between first and last assessments and (2) the num-
ber of patients with a score of 7 or less on the HAM-D scale at the
last assessment. Secondary outcome measures were the difference
between baseline and last assessment in the scores on the HAM-D
and CES-D scale, on the Modified Fatigue Impact Scale (Fischer
1999), the Perceived Deficits Questionnaire (Sullivan 1990), the
Satisfaction with Life Scale (Diener 1985), and the MOS 36-Item
Short-Form Health Questionnaire (Ware 1992).
Individual patient data was sought and kindly provided by the
study authors.
All 20patients randomized toplacebo treatment finished the study,
while 5 (23%) of the 22 patients randomized to paroxetine were
lost to follow-up before the trial ended in week 12. Three patients
(1 in the placebo and 2 in the paroxetine group) had no baseline
HAM-D score, and nine patients (1 in the placebo group, 3 in
the paroxetine group, and the 5 patients lost to follow-up) had
no HAM-D score at study end. Due to the loss to follow-up and
missing baseline and follow-up HAM-D scores, 6 of 22 patients
(27%) in the paroxetine group and 2 of 20 patients (10%) in the
placebo group could not be analysed for their HAM-D scores.
CES-D scores were available for 17 patients from the paroxetine
group and all 20 patients from the placebo group.
Seven patients (35%) in the placebo group and 12 (55%) in the
paroxetine group developed at least one adverse effect. The most
common adverse effects in the placebo group were headache in 2
(10%), and nausea and sexual dysfunction in 1 patient each. The
most common adverse effects in the paroxetine group were nausea
in 11 (50%) patients, headache and dry mouth in 9 (41%), and
sexual dysfunction in 5 (23%). Two patients from the paroxetine
group withdrew from the study due to adverse effects.
Schiffer and co-workers (Schiffer 1990) invited patients with a
diagnosis of definite multiple sclerosis according to the Poser diag-
nostic criteria (Poser 1983) who met the research diagnostic crite-
ria for definite major depressive disorder (Endicott 1979) to par-
ticipate in a randomized placebo controlled trial. The duration of
the trial was five weeks, all patients who remained in the study
for at least two weeks were included in the analyses. Patients were
assessed with the BDI and HAM-D scales at each weekly visit.
Of the 39 patients invited over a three year period, six refused to
participate and one was excluded because he had already started
antidepressant treatment elsewhere. Thirty-two patients were ran-
domized to either desipramine or placebo. Four patients were ex-
cluded within the first week after randomization: two because they
decided against taking medication (although adverse events had
not been the reason) and two others because they were found not
to have definite multiple sclerosis. It is not known to which group
these four excluded patients had been randomized. Twenty-eight
patients were included in the analyses: 14 patients received de-
sipramine, and 14 received placebo. The daily dose of desipramine
was increased during the first week from 75mg to 150mg or to
the highest dose permitted by adverse effects. The dose was also
adjusted according to serum levels of desipramine that were eval-
uated in the second week of the trial. Dose adjustments were also
made for the patients who received placebo. All patients received
psychotherapy in addition to the drug treatment. The primary
outcome of the trial was an assessment of clinical improvement of
depression by the blinded primary therapist.
Individual patient data are given in the published manuscript.
Eight patients (5 (36%) from the desipramine group and 3 (21%)
from the placebo group) were lost to follow-up before the trial
ended in week 5.
Seven patients (50%) in the placebo group and 12 (86%) in the
desipramine group developed at least one adverse effect. The most
commonly reported adverse effects were postural hypotension,
dry mouth and constipation, other adverse effects were jitteriness,
edema, dizziness and rash. More detailed data on adverse effects
are not reported.
Risk of bias in included studies
Both studies had a large number of patients lost to follow-up and
missing outcome measurements, which puts them at a high risk
of attrition bias. We defined a loss to follow-up of more than 10%
of patients as suggestive of a high risk of bias (for details see ’risk
of bias’ tables Characteristics of included studies and Figure 1 and
Figure 2).
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Effects of interventions
In both trials, a considerable (see above) number of patients was
lost to follow-up or had missing outcome measurements. Both
trials used intermediate observations to overcome this problem:
Schiffer (Schiffer 1990) included everybody in the end analysis
who participated for at least two of the five weeks of trial dura-
tion, and Ehde (Ehde 2008) carried intermediate measurements
forward to replace the measurement at the end of the trial. In our
opinion, both methods are inappropriate for dealing with missing
data.
We decided to perform an analysis of study completers, and to
estimate the effect of themissing data in these two trials by includ-
ing a sensitivity analysis with best-case and worst-case scenarios.
Due to the differences between the trials in trial duration and type
of medication, we decided not to perform a meta-analysis.
Desipramine (Analysis 1.1; Figure 3; Analysis 1.2; Figure 4;
Analysis 1.3; Figure 5; Analysis 1.4; Figure 6; ) as well as paroxetine
(Analysis 2.1; Figure 7; Analysis 2.2; Figure 8; Analysis 2.3; Figure
9; Analysis 2.4; Figure 10) treatment of depression in MS showed
a trend towards efficacy, but the confidence intervals were wide
and neither intervention had a statistically significant effect on all
outcomes. This is probably due to the small size of both trials.
Patients treated with paroxetine were significantly more likely to
drop to a HAM-D score of 7 or lower after 12 weeks of treatment
(OR 4.68, 95% confidence interval 1.04 - 21.04, p=0.04, Analysis
2.2; Figure 8).
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Figure 3. Forest plot of comparison: 1 Desipramine versus placebo, outcome: 1.1 Reduction of HAM-D
score by at least 50% at five weeks.
Figure 4. Forest plot of comparison: 1 Desipramine versus placebo, outcome: 1.2 Reduction of HAM-D
score to 7 or lower at five weeks.
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Figure 5. Forest plot of comparison: 1 Desipramine versus placebo, outcome: 1.3 Any reduction of HAM-D
score at five weeks.
Figure 6. Forest plot of comparison: 1 Desipramine versus placebo, outcome: 1.4 Any reduction of BDI
score at five weeks.
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Figure 7. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.1 Reduction of HAM-D score
by at least 50% at twelve weeks.
Figure 8. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.2 Reduction of HAM-D score
to 7 or lower at twelve weeks.
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Figure 9. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.3 Any reduction of HAM-D
score at twelve weeks.
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Figure 10. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.4 Any reduction of CES-D
score at twelve weeks.
Our sensitivity analysis showed thatmissing data had an important
influence in both trials, with large differences between best-case
and worst-case scenarios for every outcome.
Both treatments were associated with adverse effects (Analysis
1.5; Figure 11; Analysis 2.5; Figure 12; Analysis 2.6; Figure 13;
Analysis 2.7; Figure 14; Analysis 2.8; Figure 15; Analysis 2.9;
Figure 16). The analysis of the number of patients with at least
one adverse effect showed a non-significant trend towards more
adverse effects than on placebo for both desipramine (OR 6.0;
95% confidence interval: 0.97 - 37.3; p=0.05; Analysis 1.5; Figure
11) and paroxetine (OR 2.23; 95% confidence interval 0.64 -
7.74; p=0.21; Analysis 2.5; Figure 12). Significantly more patients
on paroxetine than on placebo suffered from nausea (OR 15.83;
95% confidence interval: 1.79 - 139.92; p=0.01 ; Analysis 2.7;
Figure 14) or headache (OR 7.5; 1.39 - 40.43; p=0.02; Analysis
2.8; Figure 15).
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Figure 11. Forest plot of comparison: 1 Desipramine versus placebo, outcome: 1.7 Number of patients with
at least one side effect.
Figure 12. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.5 Number of patients with at
least one side effect.
Figure 13. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.6 Number of patients with
dry mouth.
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Figure 14. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.7 Number of patients with
nausea.
Figure 15. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.8 Number of patients with
headache.
Figure 16. Forest plot of comparison: 2 Paroxetine versus placebo, outcome: 2.9 Number of patients with
sexual dysfunction.
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D I S C U S S I O N
Given the relevance of the problem of depression in MS, it was
somewhat unexpected to find only two small trials addressing its
pharmacological treatment. The small size of the trials translates
into wide confidence intervals and a relatively low reliability of the
results.
Both trials included a considerable number of patients who were
either lost to follow-up before the end of the trial or for whom
outcome measurements were missing. This problem of missing
data is the more important because of the small size of the trials.
In order to estimate the effect the missing data had on the re-
sults, we performed a sensitivity analysis with best-case and worst-
case scenarios. This analysis showed that the results of both trials
may be highly influenced by the missing data, as there were large
differences between the best-case and worst-case scenarios for all
outcomes.
Desipramine as well as paroxetine show a trend toward efficacy
for depression in MS, but confidence intervals are wide and there
were no statistically significant differences between verum and
placebo for all but one outcome (Analysis 2.2; Figure 8). On the
other hand, both treatments were associated with more adverse
effects thanplacebo,with significantlymore patients on paroxetine
than on placebo developing nausea (Analysis 2.7; Figure 14) or
headache (Analysis 2.8; Figure 15).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current literature suggests that the pharmacological treatment
of depression in MS with desipramine or paroxetine may be effec-
tive in the short term, although adverse effects are common. At
present no further evidence-based recommendations can be given.
Implications for research
Further clinical research on the pharmacologic treatment depres-
sion in MS is clearly necessary and should address the efficacy
and tolerability of antidepressants in the longer term. It would be
helpful if such trials included head-to-head comparisons between
antidepressants.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ehde 2008
Methods Double-blind randomized placebo-controlled single-center trial
Participants Patients eighteen years or older with both a diagnosis of MS confirmed by a neurologist
or MS-trained physiatrist and a diagnosis of major depressive disorder or dysthymia
Interventions Up to 40mg/day of paroxetine or placebo
Outcomes Number of patients with a reduction of at least 50% in HAM-D scores, number of
patients with a HAM-D score of seven or lower, number of patients with reduced scores
on the HAM-D and CES-D scales, difference between baseline and final scores on the
Modified Fatigue Impact Scale, the Perceived Deficits Questionnaire, the Satisfaction
with Life Scale, and the MOS 36-Item Short-Form Health Questionnaire
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization by randomization table in
blocks of ten with a computerized random
number generator. Patients were stratified
according to whether they had depression
or depression and dysthymia
Allocation concealment (selection bias) Low risk The allocation sequence was not generated
by the trial authors but by the University
of Washington Investigational Drug Ser-
vice using a computerized random number
generator
Blinding (performance bias and detection
bias)
All outcomes
Low risk The placebo capsules were similar in ap-
pearance to the paroxetine capsules. Pa-
tients and researchers were blinded to the
allocated treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk More than 10% of study participants were
lost to follow-up, which suggests a high risk
of attrition bias
An intention to treat analysis was per-
formed with all study participants with the
last observation carried forward for those
with missing data; a separate analysis was
performed with study completers. In our
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Ehde 2008 (Continued)
opinion, this method is inappropriate for
dealing with missing data
Selective reporting (reporting bias) Low risk There was no concern that outcomes were
reported selectively
Other bias Low risk The study appeared free of other problems
that could put it at a high risk of bias
Schiffer 1990
Methods Double-blind randomized placebo-controlled single center trial
Participants Patients with a diagnosis of both MS and depression according to pre-defined criteria
Interventions Up to 200mg/day of desipramine or placebo
Outcomes Main outcome measure: blinded assessment of clinical improvement by the primary
therapist, secondary outcomes: scores on the HAM-D and BDI scales
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomized with a pre-ran-
domized schedule, no further information
is given
Allocation concealment (selection bias) Low risk The randomization sequence was gener-
ated by the hospital pharmacy
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk While the clinical judgements of the pri-
mary therapist are described as blinded, it
is unclear whether the investigators admin-
istering the rating scales were blinded to
treatment allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk More than 10% of study participants were
lost to follow-up, which suggests a high risk
of attrition bias
Only study completerswere included in the
analyses. In our opinion, this method is in-
appropriate for dealing with missing data
Selective reporting (reporting bias) Low risk There was no concern that outcomes were
reported selectively
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Schiffer 1990 (Continued)
Other bias Low risk The study appeared free of other problems
that could put it at a high risk of bias
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D A T A A N D A N A L Y S E S
Comparison 1. Desipramine versus placebo




participants Statistical method Effect size
1 Reduction of HAM-D score by
at least 50% at five weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Study completers 1 20 Odds Ratio (M-H, Fixed, 95% CI) 1.4 [0.23, 8.46]
1.2 Best case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 4.5 [0.91, 22.15]
1.3 Worst case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.4 [0.08, 1.91]
2 Reduction of HAM-D score to 7
or lower at five weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Study completers 1 20 Odds Ratio (M-H, Fixed, 95% CI) 0.76 [0.10, 5.96]
2.2 Best case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 3.67 [0.70, 19.12]
2.3 Worst case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.22 [0.04, 1.39]
3 Any reduction of HAM-D score
at five weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Study completers 1 20 Odds Ratio (M-H, Fixed, 95% CI) 7.82 [0.35, 174.42]
3.2 Best case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 22.18 [1.11, 444.74]
3.3 Worst case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.49 [0.09, 2.64]
4 Any reduction of BDI score at
five weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Study completers 1 20 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.09, 6.98]
4.2 Best case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 3.33 [0.52, 21.28]
4.3 Worst case 1 28 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.03, 1.04]
5 Number of patients with at least
one adverse effect
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Intention to treat 1 28 Odds Ratio (M-H, Fixed, 95% CI) 6.0 [0.97, 37.30]
Comparison 2. Paroxetine versus placebo




participants Statistical method Effect size
1 Reduction of HAM-D score by
at least 50% at twelve weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Study completers 1 32 Odds Ratio (M-H, Fixed, 95% CI) 4.58 [0.94, 22.24]
1.2 Best case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 9.5 [2.10, 43.04]
1.3 Worst case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.30, 3.36]
2 Reduction of HAM-D score to 7
or lower at twelve weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Study completers 1 32 Odds Ratio (M-H, Fixed, 95% CI) 3.6 [0.83, 15.63]
2.2 Best case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 7.93 [1.99, 31.59]
2.3 Worst case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.30, 3.57]
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3 Any reduction of HAM-D score
at twelve weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Study completers 1 32 Odds Ratio (M-H, Fixed, 95% CI) 4.39 [0.19, 99.23]
3.2 Best case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 12.27 [0.62, 244.05]
3.3 Worst case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.04, 1.06]
4 Any reduction of CES-D score
at twelve weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Study completers 1 37 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Best case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Worst case 1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.00, 1.50]
5 Number of patients with at least
one adverse effect
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Intention to treat 1 42 Odds Ratio (M-H, Fixed, 95% CI) 2.23 [0.64, 7.74]
6 Number of patients with dry
mouth
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Intention to treat 1 42 Odds Ratio (M-H, Fixed, 95% CI) 1.55 [0.45, 5.37]
7 Number of patients with nausea 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Intention to treat 1 42 Odds Ratio (M-H, Fixed, 95% CI) 15.83 [1.79, 139.92]
8 Number of patients with
headache
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Intention to treat 1 42 Odds Ratio (M-H, Fixed, 95% CI) 7.5 [1.39, 40.43]
9 Number of patients with sexual
dysfunction
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Intention to treat 1 42 Odds Ratio (M-H, Fixed, 95% CI) 5.59 [0.59, 52.73]
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Analysis 1.1. Comparison 1 Desipramine versus placebo, Outcome 1 Reduction of HAM-D score by at least
50% at five weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 1 Desipramine versus placebo
Outcome: 1 Reduction of HAM-D score by at least 50% at five weeks
Study or subgroup Desipramine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Schiffer 1990 4/9 4/11 100.0 % 1.40 [ 0.23, 8.46 ]
Subtotal (95% CI) 9 11 100.0 % 1.40 [ 0.23, 8.46 ]
Total events: 4 (Desipramine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 Best case
Schiffer 1990 9/14 4/14 100.0 % 4.50 [ 0.91, 22.15 ]
Subtotal (95% CI) 14 14 100.0 % 4.50 [ 0.91, 22.15 ]
Total events: 9 (Desipramine), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
3 Worst case
Schiffer 1990 4/14 7/14 100.0 % 0.40 [ 0.08, 1.91 ]
Subtotal (95% CI) 14 14 100.0 % 0.40 [ 0.08, 1.91 ]
Total events: 4 (Desipramine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
0.02 0.1 1 10 50
Favours Placebo Favours Desipramine
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Analysis 1.2. Comparison 1 Desipramine versus placebo, Outcome 2 Reduction of HAM-D score to 7 or
lower at five weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 1 Desipramine versus placebo
Outcome: 2 Reduction of HAM-D score to 7 or lower at five weeks
Study or subgroup Desipramine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Schiffer 1990 2/9 3/11 100.0 % 0.76 [ 0.10, 5.96 ]
Subtotal (95% CI) 9 11 100.0 % 0.76 [ 0.10, 5.96 ]
Total events: 2 (Desipramine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
2 Best case
Schiffer 1990 7/14 3/14 100.0 % 3.67 [ 0.70, 19.12 ]
Subtotal (95% CI) 14 14 100.0 % 3.67 [ 0.70, 19.12 ]
Total events: 7 (Desipramine), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
3 Worst case
Schiffer 1990 2/14 6/14 100.0 % 0.22 [ 0.04, 1.39 ]
Subtotal (95% CI) 14 14 100.0 % 0.22 [ 0.04, 1.39 ]
Total events: 2 (Desipramine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
0.01 0.1 1 10 100
Favours Placebo Favours Desipramine
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Analysis 1.3. Comparison 1 Desipramine versus placebo, Outcome 3 Any reduction of HAM-D score at five
weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 1 Desipramine versus placebo
Outcome: 3 Any reduction of HAM-D score at five weeks
Study or subgroup Desipramine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Schiffer 1990 9/9 8/11 100.0 % 7.82 [ 0.35, 174.42 ]
Subtotal (95% CI) 9 11 100.0 % 7.82 [ 0.35, 174.42 ]
Total events: 9 (Desipramine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Best case
Schiffer 1990 14/14 8/14 100.0 % 22.18 [ 1.11, 444.74 ]
Subtotal (95% CI) 14 14 100.0 % 22.18 [ 1.11, 444.74 ]
Total events: 14 (Desipramine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.043)
3 Worst case
Schiffer 1990 9/14 11/14 100.0 % 0.49 [ 0.09, 2.64 ]
Subtotal (95% CI) 14 14 100.0 % 0.49 [ 0.09, 2.64 ]
Total events: 9 (Desipramine), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
0.01 0.1 1 10 100
Favours Placebo Favours Desipramine
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Analysis 1.4. Comparison 1 Desipramine versus placebo, Outcome 4 Any reduction of BDI score at five
weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 1 Desipramine versus placebo
Outcome: 4 Any reduction of BDI score at five weeks
Study or subgroup Desipramine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Schiffer 1990 7/9 9/11 100.0 % 0.78 [ 0.09, 6.98 ]
Subtotal (95% CI) 9 11 100.0 % 0.78 [ 0.09, 6.98 ]
Total events: 7 (Desipramine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
2 Best case
Schiffer 1990 12/14 9/14 100.0 % 3.33 [ 0.52, 21.28 ]
Subtotal (95% CI) 14 14 100.0 % 3.33 [ 0.52, 21.28 ]
Total events: 12 (Desipramine), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
3 Worst case
Schiffer 1990 7/14 12/14 100.0 % 0.17 [ 0.03, 1.04 ]
Subtotal (95% CI) 14 14 100.0 % 0.17 [ 0.03, 1.04 ]
Total events: 7 (Desipramine), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
0.01 0.1 1 10 100
Favours Placebo Favours Desipramine
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Analysis 1.5. Comparison 1 Desipramine versus placebo, Outcome 5 Number of patients with at least one
adverse effect.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 1 Desipramine versus placebo
Outcome: 5 Number of patients with at least one adverse effect
Study or subgroup Desipramine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intention to treat
Schiffer 1990 12/14 7/14 100.0 % 6.00 [ 0.97, 37.30 ]
Subtotal (95% CI) 14 14 100.0 % 6.00 [ 0.97, 37.30 ]
Total events: 12 (Desipramine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
0.01 0.1 1 10 100
Favours Desipramine Favours Placebo
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Analysis 2.1. Comparison 2 Paroxetine versus placebo, Outcome 1 Reduction of HAM-D score by at least
50% at twelve weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 1 Reduction of HAM-D score by at least 50% at twelve weeks
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Ehde 2008 11/14 8/18 100.0 % 4.58 [ 0.94, 22.24 ]
Subtotal (95% CI) 14 18 100.0 % 4.58 [ 0.94, 22.24 ]
Total events: 11 (Paroxetine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
2 Best case
Ehde 2008 19/22 8/20 100.0 % 9.50 [ 2.10, 43.04 ]
Subtotal (95% CI) 22 20 100.0 % 9.50 [ 2.10, 43.04 ]
Total events: 19 (Paroxetine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.92 (P = 0.0035)
3 Worst case
Ehde 2008 11/22 10/20 100.0 % 1.00 [ 0.30, 3.36 ]
Subtotal (95% CI) 22 20 100.0 % 1.00 [ 0.30, 3.36 ]
Total events: 11 (Paroxetine), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.02 0.1 1 10 50
Favours Placebo Favours Paroxetine
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Analysis 2.2. Comparison 2 Paroxetine versus placebo, Outcome 2 Reduction of HAM-D score to 7 or lower
at twelve weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 2 Reduction of HAM-D score to 7 or lower at twelve weeks
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Ehde 2008 9/14 6/18 100.0 % 3.60 [ 0.83, 15.63 ]
Subtotal (95% CI) 14 18 100.0 % 3.60 [ 0.83, 15.63 ]
Total events: 9 (Paroxetine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
2 Best case
Ehde 2008 17/22 6/20 100.0 % 7.93 [ 1.99, 31.59 ]
Subtotal (95% CI) 22 20 100.0 % 7.93 [ 1.99, 31.59 ]
Total events: 17 (Paroxetine), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
3 Worst case
Ehde 2008 9/22 8/20 100.0 % 1.04 [ 0.30, 3.57 ]
Subtotal (95% CI) 22 20 100.0 % 1.04 [ 0.30, 3.57 ]
Total events: 9 (Paroxetine), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
0.02 0.1 1 10 50
Favours Placebo Favours Paroxetine
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Analysis 2.3. Comparison 2 Paroxetine versus placebo, Outcome 3 Any reduction of HAM-D score at
twelve weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 3 Any reduction of HAM-D score at twelve weeks
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Ehde 2008 14/14 16/18 100.0 % 4.39 [ 0.19, 99.23 ]
Subtotal (95% CI) 14 18 100.0 % 4.39 [ 0.19, 99.23 ]
Total events: 14 (Paroxetine), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
2 Best case
Ehde 2008 22/22 16/20 100.0 % 12.27 [ 0.62, 244.05 ]
Subtotal (95% CI) 22 20 100.0 % 12.27 [ 0.62, 244.05 ]
Total events: 22 (Paroxetine), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
3 Worst case
Ehde 2008 14/22 18/20 100.0 % 0.19 [ 0.04, 1.06 ]
Subtotal (95% CI) 22 20 100.0 % 0.19 [ 0.04, 1.06 ]
Total events: 14 (Paroxetine), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
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Analysis 2.4. Comparison 2 Paroxetine versus placebo, Outcome 4 Any reduction of CES-D score at twelve
weeks.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 4 Any reduction of CES-D score at twelve weeks
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Study completers
Ehde 2008 17/17 20/20 Not estimable
Subtotal (95% CI) 17 20 Not estimable
Total events: 17 (Paroxetine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Best case
Ehde 2008 22/22 20/20 Not estimable
Subtotal (95% CI) 22 20 Not estimable
Total events: 22 (Paroxetine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Worst case
Ehde 2008 17/22 20/20 100.0 % 0.08 [ 0.00, 1.50 ]
Subtotal (95% CI) 22 20 100.0 % 0.08 [ 0.00, 1.50 ]
Total events: 17 (Paroxetine), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
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Analysis 2.5. Comparison 2 Paroxetine versus placebo, Outcome 5 Number of patients with at least one
adverse effect.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 5 Number of patients with at least one adverse effect
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intention to treat
Ehde 2008 12/22 7/20 100.0 % 2.23 [ 0.64, 7.74 ]
Subtotal (95% CI) 22 20 100.0 % 2.23 [ 0.64, 7.74 ]
Total events: 12 (Paroxetine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
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Analysis 2.6. Comparison 2 Paroxetine versus placebo, Outcome 6 Number of patients with dry mouth.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 6 Number of patients with dry mouth
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intention to treat
Ehde 2008 10/22 7/20 100.0 % 1.55 [ 0.45, 5.37 ]
Subtotal (95% CI) 22 20 100.0 % 1.55 [ 0.45, 5.37 ]
Total events: 10 (Paroxetine), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 2.7. Comparison 2 Paroxetine versus placebo, Outcome 7 Number of patients with nausea.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 7 Number of patients with nausea
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intention to treat
Ehde 2008 10/22 1/20 100.0 % 15.83 [ 1.79, 139.92 ]
Subtotal (95% CI) 22 20 100.0 % 15.83 [ 1.79, 139.92 ]
Total events: 10 (Paroxetine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
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Analysis 2.8. Comparison 2 Paroxetine versus placebo, Outcome 8 Number of patients with headache.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 8 Number of patients with headache
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intention to treat
Ehde 2008 10/22 2/20 100.0 % 7.50 [ 1.39, 40.43 ]
Subtotal (95% CI) 22 20 100.0 % 7.50 [ 1.39, 40.43 ]
Total events: 10 (Paroxetine), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
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Analysis 2.9. Comparison 2 Paroxetine versus placebo, Outcome 9 Number of patients with sexual
dysfunction.
Review: Pharmacologic treatment of depression in multiple sclerosis
Comparison: 2 Paroxetine versus placebo
Outcome: 9 Number of patients with sexual dysfunction
Study or subgroup Paroxetine Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intention to treat
Ehde 2008 5/22 1/20 100.0 % 5.59 [ 0.59, 52.73 ]
Subtotal (95% CI) 22 20 100.0 % 5.59 [ 0.59, 52.73 ]
Total events: 5 (Paroxetine), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
0.01 0.1 1 10 100
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